Inovio Pharmaceuticals Inc (NASDAQ:INO) has a beta value of 1.42 and has seen 2.52 million shares traded in the last trading session. The INO stock price is -806.62% off its 52-week high price of $12.33 and 4.41% above the 52-week low of $1.30. If we look at the company’s 10-day average daily trading volume, we find that it stood at 4.9 million shares traded. The 3-month trading volume is 1.33 million shares.
The consensus among analysts is that Inovio Pharmaceuticals Inc (INO) is Buy stock at the moment, with a recommendation rating of 1.67. 0 analysts rate the stock as a Sell, while 0 rate it as Overweight. 1 out of 3 have rated it as a Hold, with 2 advising it as a Buy. 0 have rated the stock as Underweight.
Inovio Pharmaceuticals Inc (NASDAQ:INO) trade information
Over the past 30 days, the shares of Inovio Pharmaceuticals Inc (NASDAQ:INO) have changed -35.85%. Short interest in the company has seen 6.46 million shares shorted with days to cover at 9.44.
Wall Street analysts have a consensus price target for the stock at $20, which means that the shares’ value could jump 93.2% from current levels. The projected low price target is $8.0 while the price target rests at a high of $40.0. In that case, then, we find that the current price level is -2841.18% off the targeted high while a plunge would see the stock gain -488.24% from current levels.
Inovio Pharmaceuticals Inc (INO) estimates and forecasts
The company’s shares have lost -34.93% over the past 6 months.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was 22.92% over the past 5 years. Earnings growth for 2025 is a modest 48.65% while over the next 5 years, the company’s earnings are expected to increase by 39.23%.
INO Dividends
Inovio Pharmaceuticals Inc is expected to release its next earnings report on 2025-May-13 this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
Inovio Pharmaceuticals Inc (NASDAQ:INO)’s Major holders
Insiders own 0.73% of the company shares, while shares held by institutions stand at 37.28% with a share float percentage of 37.56%. Investors are also buoyed by the number of investors in a company, with Inovio Pharmaceuticals Inc having a total of 146.0 institutions that hold shares in the company. The top two institutional holders are DEEP TRACK CAPITAL, LP with over 2.07 million shares worth more than $16.7 million. As of 2024-06-30, DEEP TRACK CAPITAL, LP held 7.5988% of shares outstanding.
The other major institutional holder is BLACKROCK INC., with the holding of over 1.71 million shares as of 2024-06-30. The firm’s total holdings are worth over $13.79 million and represent 6.2741% of shares outstanding.
Also the top two Mutual Funds that are holding company’s shares are VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund and iShares Trust-iShares Russell 2000 ETF . As of Mar 31, 2025 , the former fund manager holds about 3.09% shares in the company for having 1.13 shares of worth $1.54 million while later fund manager owns 847.35 shares of worth $1.15 million as of May 31, 2025 , which makes it owner of about 2.31% of company’s outstanding stock.
